EVMN

Latest SEC Filings & News for EVMN

2 most recent filings and news items mentioning EVMN. Updated every 60 seconds.

Get this data via API — free tier: 10,000 calls/day

curl "https://api.brieftape.com/v1/tickers/EVMN/news?limit=20"

Pull EVMN filings straight into your trading bot, model, or app.

Get an API key — free tier: 10,000 calls/day

OfferingJul 30, 2026Neutral

Evommune Doses First Patient in Phase 2b Migraine Trial

Evommune initiated a Phase 2b trial for EVO756 in migraine prophylaxis. This offering a new oral therapeutic option for patients not responding adequately to current treatments. The data is expected in 2027.

View filing at SEC.gov →

OtherJun 29, 2026Positive

Evommune pivots EVO756 away from CSU after Phase 2b trial failure

Evommune disclosed that its Phase 2b trial of EVO756 failed to meet the primary endpoint for chronic spontaneous urticaria. The company will discontinue development in this indication but will use its cash runway to advance the candidate in atopic dermatitis and migraine.

View filing at SEC.gov →

AI-summarized public filings for informational purposes only. Not investment advice. Always verify against the original filing at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.